Increased human defensine levels hint at an inflammatory etiology of bisphosphonate-associated osteonecrosis of the jaw: An immunohistological study

Journal of Translational Medicine

Emeka Nkenke²  Friedrich W Neukam²  Susanne Trabert²  Florian Stelzle²  Stephan Schwarz-Furlan¹  Falk Wehrhan²  Philipp Stockmann² 

[1] Department of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany;Department of Oral and Maxillofacial Surgery, University of Erlangen-Nuremberg, Erlangen, Germany

关键词: innate immunity;    human beta defensins;    osteoradionecrosis;    bisphosphonate-associated osteonecrosis;    antimicrobial peptide;   

Others  :  1207883
DOI  :  10.1186/1479-5876-9-135

 received in 2011-03-09, accepted in 2011-08-15,  发布年份 2011

【 摘 要 】

Background

Human β-defensins (hBD) are antimicrobial peptides that are an integral part of bone innate immunity. Recently, it could be shown that expression of hBD-1, -2 and -3 were upregulated in cases of osteomyelitis of the jaws. In order to gain insight into the possible impairment of hBD metabolism in bisphosphonate-associated osteonecrosis of the jaws (BONJ), the present exploratory study was designed so as to determine the qualitative and quantitative expression of afore mentioned hBDs in BONJ and infected osteoradionecrosis (ORN), both of which represent inflammatory bone diseases.

Methods

Bone samples were collected from patients with BONJ (n = 20) and ORN (n = 20). Non-infected healthy bone samples (n = 20) were included as controls. Immunohistological staining in an autostainer was carried out by the (Strept-ABC)-method against hBD-1,-2,-3. Specific positive vs. negative cell reaction of osteocytes (labeling index) near the border of bony resection was determined and counted for quantitative analysis. Number of vital osteocytes vs. empty osteocytes lacunae was compared between groups.

Results

hBD-1,-2 and -3 could be detected in BONJ as well as ORN and healthy bone samples. Immunoreactivity against hBD-2 and -3 was significantly higher in BONJ than in ORN and healthy jaw bone samples. Number of empty osteocyte lacunae was significantly higher in ORN compared with BONJ (P = 0.001).

Conclusion

Under the condition of BONJ an increased expression of hBD-1,-2,-3 is detectable, similarly to the recently described upregulation of defensins in chronically infected jaw bones. It remains still unclear how these findings may relate to the pathoetiology of these diseases and whether this is contributing to the development of BONJ and ORN or simply an after effect of the disease.

【 授权许可】

   
2011 Stockmann et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Hansen T, Kunkel M, Weber A, James Kirkpatrick C: Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 2006, 35:155-160.
• [2]Stockmann P, Hinkmann FM, Lell MM, Fenner M, Vairaktaris E, Neukam FW, Nkenke E: Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. Clin Oral Investig 2009.
• [3]Nair SP, Meghji S, Wilson M, Reddi K, White P, Henderson B: Bacterially induced bone destruction: mechanisms and misconceptions. Infect Immun 1996, 64:2371-2380.
• [4]Hansen T, Kunkel M, Springer E, Walter C, Weber A, Siegel E, Kirkpatrick CJ: Actinomycosis of the jaws-histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch 2007, 451:1009-1017.
• [5]Hall V: Actinomyces--gathering evidence of human colonization and infection. Anaerobe 2008, 14:1-7.
• [6]Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002, 347:1151-1160.
• [7]Kagan BL, Ganz T, Lehrer RI: Defensins: a family of antimicrobial and cytotoxic peptides. Toxicology 1994, 87:131-149.
• [8]Gallo RL, Huttner KM: Antimicrobial peptides: an emerging concept in cutaneous biology. J Invest Dermatol 1998, 111:739-743.
• [9]Wenghoefer M, Pantelis A, Dommisch H, Gotz W, Reich R, Berge S, Martini M, Allam JP, Jepsen S, Merkelbach-Bruse S, et al.: Nuclear hBD-1 accumulation in malignant salivary gland tumours. BMC Cancer 2008, 8:290. BioMed Central Full Text
• [10]Wenghoefer M, Pantelis A, Dommisch H, Reich R, Martini M, Allam JP, Novak N, Berge S, Jepsen S, Winter J: Decreased gene expression of human beta-defensin-1 in the development of squamous cell carcinoma of the oral cavity. Int J Oral Maxillofac Surg 2008, 37:660-663.
• [11]Pazgier M, Hoover DM, Yang D, Lu W, Lubkowski J: Human beta-defensins. Cell Mol Life Sci 2006, 63:1294-1313.
• [12]Wimalawansa SJ: Insight into bisphosphonate-associated osteomyelitis of the jaw: pathophysiology, mechanisms and clinical management. Expert Opin Drug Saf 2008, 7:491-512.
• [13]Schibli DJ, Hunter HN, Aseyev V, Starner TD, Wiencek JM, McCray PB, Tack BF, Vogel HJ: The solution structures of the human beta-defensins lead to a better understanding of the potent bactericidal activity of HBD3 against Staphylococcus aureus. J Biol Chem 2002, 277:8279-8289.
• [14]Warnke PH, Springer IN, Russo PA, Wiltfang J, Essig H, Kosmahl M, Sherry E, Acil Y: Innate immunity in human bone. Bone 2006, 38:400-408.
• [15]AAOMS: American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007, 65:369-376.
• [16]Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, et al.: Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22:1479-1491.
• [17]Stockmann P, Vairaktaris E, Wehrhan F, Seiss M, Schwarz S, Spriewald B, Neukam FW, Nkenke E: Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer 2010, 18:449-460.
• [18]Marx RE: Osteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg 1983, 41:283-288.
• [19]Marx RE, Sawatari Y, Fortin M, Broumand V: Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005, 63:1567-1575.
• [20]Wehrhan F, Hyckel P, Guentsch A, Nkenke E, Stockmann P, Schlegel KA, Neukam FW, Amann K: Bisphosphonate-associated osteonecrosis of the jaw is linked to suppressed TGFbeta1-signaling and increased Galectin-3 expression: A histological study on biopsies. J Transl Med 2011, 9:102. BioMed Central Full Text
• [21]Reid IR: Osteonecrosis of the jaw - Who gets it, and why? Bone 2008.
• [22]Reid IR, Bolland MJ, Grey AB: Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone 2007, 41:318-320.
• [23]Otto S, Pautke C, Opelz C, Westphal I, Drosse I, Schwager J, Bauss F, Ehrenfeld M, Schieker M: Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism. J Oral Maxillofac Surg 2010, 68:2837-2845.
• [24]Abiko Y, Saitoh M, Nishimura M, Yamazaki M, Sawamura D, Kaku T: Role of beta-defensins in oral epithelial health and disease. Med Mol Morphol 2007, 40:179-184.
• [25]Murphy CJ, Foster BA, Mannis MJ, Selsted ME, Reid TW: Defensins are mitogenic for epithelial cells and fibroblasts. J Cell Physiol 1993, 155:408-413.
• [26]Fleischmann J, Selsted ME, Lehrer RI: Opsonic activity of MCP-1 and MCP-2, cationic peptides from rabbit alveolar macrophages. Diagn Microbiol Infect Dis 1985, 3:233-242.
• [27]Kraus D, Deschner J, Jager A, Wenghoefer M, Bayer S, Jepsen S, Allam J, Novak N, Meyer R, Winter J: Human beta-defensins differently affect proliferation, differentiation, and mineralization of osteoblast-like MG63 cells. J Cell Physiol 2011.
• [28]Harder J, Bartels J, Christophers E, Schroder JM: A peptide antibiotic from human skin. Nature 1997, 387:861.
• [29]Sorensen OE, Cowland JB, Theilgaard-Monch K, Liu L, Ganz T, Borregaard N: Wound healing and expression of antimicrobial peptides/polypeptides in human keratinocytes, a consequence of common growth factors. J Immunol 2003, 170:5583-5589.
• [30]Wolf AM, Rumpold H, Tilg H, Gastl G, Gunsilius E, Wolf D: The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica 2006, 91:1165-1171.
• [31]Yang D, Chertov O, Bykovskaia SN, Chen Q, Buffo MJ, Shogan J, Anderson M, Schroder JM, Wang JM, Howard OM, Oppenheim JJ: Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science 1999, 286:525-528.
• [32]Chen YJ, Chao KS, Yang YC, Hsu ML, Lin CP, Chen YY: Zoledronic acid, an aminobisphosphonate, modulates differentiation and maturation of human dendritic cells. Immunopharmacol Immunotoxicol 2009.
• [33]Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, Darst MA, Gao B, Boguniewicz M, Travers JB, Leung DY: Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 2003, 171:3262-3269.
• [34]Agrati C, Cimini E, Sacchi A, Bordoni V, Gioia C, Casetti R, Turchi F, Tripodi M, Martini F: Activated V gamma 9V delta 2 T cells trigger granulocyte functions via MCP-2 release. J Immunol 2009, 182:522-529.
• [35]Varoga D, Tohidnezhad M, Paulsen F, Wruck CJ, Brandenburg L, Mentlein R, Lippross S, Hassenpflug J, Besch L, Muller M, et al.: The role of human beta-defensin-2 in bone. J Anat 2008, 213:749-757.
• [36]Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW: Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg 2008, 66:767-775.
• [37]Favia G, Pilolli GP, Maiorano E: Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone 2009, 45:406-413.
• [38]Bissell J, Joly S, Johnson GK, Organ CC, Dawson D, McCray PB, Guthmiller JM: Expression of beta-defensins in gingival health and in periodontal disease. J Oral Pathol Med 2004, 33:278-285.
• [39]Varoga D, Wruck CJ, Tohidnezhad M, Brandenburg L, Paulsen F, Mentlein R, Seekamp A, Besch L, Pufe T: Osteoblasts participate in the innate immunity of the bone by producing human beta defensin-3. Histochem Cell Biol 2009, 131:207-218.
• [40]Migliorati CA: Bisphosphonate-associated oral osteonecrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005, 99:135.